Internal link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement October 25, 2024 at 08:45 PM UTC
Internal link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement October 23, 2024 at 02:15 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares October 22, 2024 at 08:01 PM UTC
Internal link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society October 07, 2024 at 12:00 PM UTC
Internal link ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference September 10, 2024 at 08:30 PM UTC
Internal link ProQR Announces Second Quarter 2024 Operating and Financial Results August 08, 2024 at 11:00 AM UTC
Internal link ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit June 18, 2024 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2024 Operating and Financial Results May 09, 2024 at 11:00 AM UTC
Internal link ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases May 08, 2024 at 12:00 PM UTC
Internal link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 April 23, 2024 at 11:00 AM UTC
Internal link ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting April 22, 2024 at 08:31 PM UTC
Internal link ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio April 19, 2024 at 11:00 AM UTC
Internal link ProQR Announces Year End 2023 Operating and Financial Results March 13, 2024 at 11:00 AM UTC
Internal link ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing February 15, 2024 at 12:00 PM UTC
Internal link ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 January 19, 2024 at 12:00 PM UTC
Internal link ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration January 05, 2024 at 12:00 PM UTC
Internal link ProQR Announces Extraordinary General Meeting of Shareholders December 27, 2017 at 12:00 PM UTC
Internal link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa November 29, 2017 at 12:00 PM UTC
Internal link ProQR to Present at the Annual Piper Jaffray Healthcare Conference November 21, 2017 at 12:00 PM UTC
Internal link ProQR Announces Results for the Third Quarter of 2017 November 20, 2017 at 12:00 PM UTC
Internal link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares November 14, 2017 at 12:44 PM UTC
Internal link ProQR Announces Proposed Public Offering of Ordinary Shares November 13, 2017 at 09:01 PM UTC
Internal link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness November 13, 2017 at 12:00 PM UTC
Internal link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board November 09, 2017 at 12:00 PM UTC